<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886509</url>
  </required_header>
  <id_info>
    <org_study_id>199/2008</org_study_id>
    <nct_id>NCT00886509</nct_id>
  </id_info>
  <brief_title>Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients</brief_title>
  <official_title>Subcutaneous Administration of Pegylated Granulocyte-Colony Stimulating Factor for Long-Term Promotion of Collateral Growth in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in patients with stable coronary artery disease (CAD) treatable by
      PCI (percutaneous coronary intervention) is to evaluate the long-term efficacy and safety of
      subcutaneously applied, pegylated granulocyte colony stimulating factor (Pegfilgrastim,
      PEG-G-CSF; NeulastaÂ®, Amgen Switzerland) with regard to the promotion of collateral growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary artery disease (CAD) is the leading cause of death in industrialized countries.
      Current revascularization therapies are PCI or surgical revascularization. However, inherent
      to them are procedure-related risks and the fact, that progression of CAD is not prevented.
      Additionally, up to one fourth of all CAD patients are not amenable to standard
      revascularization therapies. Thus, there is a need for alternative therapies. The coronary
      collateral circulation is prevalent in humans, and in CAD the amount of collateral flow is a
      pivotal protective factor with respect to infarct size, all-cause- and cardiac mortality.
      Coronary collateral growth promotion is an alternative to conventional revascularization
      which can be achieved by cytokine-based approaches (e.g. with colony-stimulating
      factor-therapy) in humans. The goal of collateral promotion is to reduce myocardial damage in
      case of a coronary occlusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Collateral flow index (CFI)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial blood flow (MBF) during hyperemia</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Collateral promotion; PCI after 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First pegGCSF or placebo; PCI after 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Collateral promotion after PCI at baseline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Collateral promotion with pegGCSF after PCI at baseline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
    <description>s.c. administration of pegylated G-CSF over 6 months</description>
    <arm_group_label>Collateral promotion; PCI after 6 months</arm_group_label>
    <arm_group_label>Collateral promotion after PCI at baseline</arm_group_label>
    <other_name>Peg-GCSF</other_name>
    <other_name>Peg-G-CSF</other_name>
    <other_name>PEG-rmetHuG-CSF</other_name>
    <other_name>Amgen brand of pegfilgrastim</other_name>
    <other_name>Neulasta</other_name>
    <other_name>pegylated (r-G-CSF)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo control Arm 1: Collateral promotion; PCI after 6 months</description>
    <arm_group_label>Collateral promotion; PCI after 6 months</arm_group_label>
    <other_name>Placebo control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years old

          2. 1- to 3-vessel coronary artery disease (CAD)

          3. Stable angina pectoris

          4. At least 1 stenotic lesion suitable for PCI

          5. No Q-wave myocardial infarction in the area undergoing CFI measurement

          6. Written informed consent to participate in the study

        Exclusion Criteria:

          1. Acute myocardial infarction

          2. Unstable CAD

          3. CAD treated best by CABG

          4. Patients with overt neoplastic disease

          5. Patients with diabetic retinopathy

          6. Liver or kidney disease

          7. Pre-menopausal women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Seiler, MD, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Traupe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Berne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Stoller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Berne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Berne</name>
      <address>
        <city>Berne</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Meier P, Gloekler S, de Marchi SF, Indermuehle A, Rutz T, Traupe T, Steck H, Vogel R, Seiler C. Myocardial salvage through coronary collateral growth by granulocyte colony-stimulating factor in chronic coronary artery disease: a controlled randomized trial. Circulation. 2009 Oct 6;120(14):1355-63. doi: 10.1161/CIRCULATIONAHA.109.866269. Epub 2009 Sep 21.</citation>
    <PMID>19770393</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <last_update_submitted>December 15, 2015</last_update_submitted>
  <last_update_submitted_qc>December 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Stable</keyword>
  <keyword>Coronary Collaterals</keyword>
  <keyword>Therapeutic Collateral Promotion (TCP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

